Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

Table 1 Key phase II and III studies using irinotecan in pediatric sarcoma patients

Reference	Lead author	Phase	Other agents given with irinotecan	Population	Comments
[30]	Hawkins	III	Vincristine	Newly-diagnosed intermediate-risk RMS	VI alternating with VAC is as efficacious as VAC alone, and may reduce long-term toxicity
[15]	Pappo	II	Vincristine	Newly-diagnosed metastatic RMS	Response rate to induction rose from 46–70 % after addition of vincristine
[38]	Dharmajan	II	Carboplatin, radiation	Newly-diagnosed intermediate or high-risk RMS	Local control rate of 89 %; reduced mucositis compared to historical controls
[10]	Mascarenhas	II	Vincristine	Relapsed RMS	Similar rates of response and grade 3–4 toxicity between d × 5 vs d × 5 × 2 schedule
[37]	Mixon	II	Temozolomide, vincristine	Relapsed RMS	One complete response in 4 patients
[33]	Kurucu	II	Temozolomide	Relapsed ES	Response rate 55 %
[34]	Wagner	II	Temozolomide	Relapsed ES	Response rate 29 %
[35]	Casey	II	Temozolomide	Relapsed ES	Response rate 63 %
[36]	Raciborska	II	Temozolomide, vincristine	Relapsed ES	Response rate 68 %
[43]	Yoon	II	Docetaxel	Relapsed ES	Response rate 33 %
[42]	Crews	II	Ifosfamide	Newly-diagnosed high-risk osteosarcoma	Ifosfamide reduced SN-38 exposures

ISSN: 2045-3329